The 5 most recent market catalysts affecting $MPLT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 75
UBS Downgrades MapLight Therapeutics to Neutral, Lowers Price Target to $13
UBS analyst Ashwani Verma downgraded MapLight Therapeutics (MPLT) from a 'Buy' rating to 'Neutral' and drastically cut the price target from $52 to $13. This action signals a signi…
Jul 28, 2026
Corporate Catalyst
Bearish
Impact 65
Morgan Stanley Downgrades MapLight Therapeutics to Equal-Weight, Lowers Price Target to $21
Morgan Stanley analyst Sean Laaman downgraded MapLight Therapeutics (MPLT) from 'Overweight' to 'Equal-Weight' and slashed the price target from $34 to $21. This move indicates a s…
Jul 27, 2026
Corporate Catalyst
Bearish
Impact 95
MapLight Therapeutics Stock Falls Despite Schizophrenia Drug Meeting Main Trial Goal
MapLight Therapeutics reported that its schizophrenia drug, ML-007C-MA, successfully met its primary endpoint in a Phase 2 trial with a twice-daily dose. However, a once-daily dose…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 55
UBS Maintains Buy on MapLight Therapeutics, Raises Price Target to $52
UBS analyst Ashwani Verma maintained a 'Buy' rating on MapLight Therapeutics (MPLT) and raised the price target from $48 to $52. This action signals increased confidence from a pro…
Jul 21, 2026
Corporate Catalyst
Neutral
Impact 65
BMO Capital Initiates Coverage On MapLight Therapeutics with Outperform Rating, Announces Price Target of $46
BMO Capital's initiation of coverage on MapLight Therapeutics (MPLT) with an 'Outperform' rating and a $46 price target is a positive development for the company. Analyst coverage,…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.